T2 Biosystems sold four T2Dx® Instruments to expand its international presence in sepsis-testing technology.Quiver AI SummaryT2 Biosystems, Inc. announced the sale of four T2Dx® Instruments to its European...
T2 Biosystems extends its agreement with Vizient, enhancing hospital access to rapid sepsis diagnostics through 2026.Quiver AI SummaryT2 Biosystems, Inc. has announced the extension of its supplier agreement...
T2 Biosystems announced plans to license its technology for direct-from-whole-blood detection of sepsis-causing pathogens, aiming to expand market access.Quiver AI SummaryT2 Biosystems, Inc. has announced...
/Cardinal%20Health%2C%20Inc_%20logo%20on%20building%20by-%20JHVEPhoto%20via%20Shutterstock.jpg)
Cardinal Health is expected to release its fiscal first-quarter earnings next month, and analysts project a single-digit profit decline.